hrp0095p1-238 | Diabetes and Insulin | ESPE2022

Faster-acting insulin Fiasp vs insulin Novorapid in type 1 diabetes children and adolescents with sensor-augmented pump therapy

Xatzipsalti Maria , Triantafillidou Antigoni , Kourousi Giannoula , Patouni Konstantina , Bourousis Evangelos , Kassari Elisavet , Delis Dimitrios , Vazeou Andriani

Introduction: Rapid-acting insulin analogues have been developed to mimic more closely the physiological action of endogenous insulin. However, they still have a delayed onset of action and a longer duration compares to endogenous insulin. Therefore, newer insulin analogues have been developed with a faster onset and a shorter duration of action.Aim: To evaluate the efficacy of rapid-acting insulin analogues (Novorapid) ...

hrp0095p1-270 | Fat, Metabolism and Obesity | ESPE2022

Homology modelling analysis provides insight into ADCY3, a candidate obesity gene

Toumba Meropi , Fanis Pavlos , Neocleous Vassos , Vlachakis Dimitrios , Phylactou Leonidas , Skordis Nicos , Mantzoros Christos , Pantelidou Maria

Background: In an effort to better understand the molecular basis of obesity, studies focus on genetic loci mapping to the leptin–melanocortin pathway, one of the key mechanisms for controlling food intake and body weight. Adenylate cyclase 3 (ADCY3) is a key genetic candidate as it seems to have an essential role at primary neuronal cilia in regulating body weight. We have previously reported the novel probably pathogenic ADCY3</em...

hrp0092p1-16 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Normocalcemic Hyperparathyroidism in Children

Papadimitriou Dimitrios T. , Dermitzaki Eleni , Kleanthous Kleanthis , Papadimitriou Anastasios , Mastorakos George

Normocalcemic primary hyperparathyroidism (NPHPT) has been recognized as a variant of primary hyperparathyroidism (PHPT) and it is characterized by elevated PTH with persistently normal concentrations of albumin-adjusted total and ionized calcium. It is related to increased risk in development of osteopenia/osteoporosis as well of parathyroid adenoma and hypercalcemia/hypercalciuria. In order to identify biochemical disorders of PTH in normocalcemic children we performed in al...

hrp0092p3-301 | Late Breaking Abstracts | ESPE2019

A novel heterozygous mutation in the SLC5A2 gene causing mild failure to thrive and subclinical hypoglycemia in a 2-year old girl

Dermitzaki Eleni , Manolakos Emmanouil , Filiousi Fotini , Kleanthous Kleanthis , Papadimitriou Dimitrios T.

Patients: A 2-year old girl was referred due to glucosuria 1874 mg/dl. Fasting blood sugar was 71 mg/dl and HbA1c 4.8%. Examination of her growth charts revealed mild failure to thrive, since 15 months of age, as far as weight gain and height velocity. We used Flash technology (FreeStyle Libre) to identify hypoglycemic episodes. In 9 days, 8% of the time was < 70 mg/dl, with 11 hypoglycemic events: mean duration 94 min, lowest 52 mg/dl.<p class...

hrp0089rfc9.4 | Pituitary, Neuroendocrinology and Puberty 1 | ESPE2018

REplacement of MAle mini-Puberty in Neonates and Children with Micropenis and Cryptorchidism due to Hypogonadotropic Hypogonadism: Results of the ‘REMAP’ Study ISRCTN13007297

Papadimitriou Dimitrios T , Chrysis Dionysios , Nyktari Georgia , Zoupanos George , Liakou Eleni , Papadimitriou Anastasios , Mastorakos George

Background: Hormonal replacement in boys with congenital Hypogonadotrophic Hypogonadism (HH) as well as hormonal repair of bilateral cryptorchidism and micropenis remain a challenge in pediatric endocrinology.Methods: In the «REMAP» study ISRCTN13007297 eight neonates and infants, all with bilateral cryptorchidism in intra-abdominal position and micropenis (≤2 cm), with absence of neonatal male-mini puberty were treated for 3 months with ...

hrp0089rfc13.4 | Pituitary, Neuroendocrinology and Puberty 2 | ESPE2018

Gain in Predicted Adult Height Using the Combination of an LHRH Analogue and an Aromatase Inhibitor in Early Maturing Girls with Compromised Growth for 2 yrs or Until the Age of 11 is Maintained and Further Improved by Aromatase Inhibitor Monotherapy: Results on Final Height of the ‘GAIL’ Study ISRCTN11469487

Papadimitriou Dimitrios T , Dermitzaki Eleni , Papagianni Maria , Kleanthous Kleanthis , Attilakos Achilleas , Mastorakos George , Papadimitriou Anastasios

Background: Third generation aromatase inhibitors (AI) have never been used as monotherapy to increase predicted adult height (PAH) in girls. Our previously published GAIL study (J Endocrinol Invest. 2016 Apr;39(4):439–46) has shown that the combination of anastrozole to an LHRH analogue for 24 months is safe and effective in ameliorating PAH in girls with early puberty +1.21 SDS (+7.51 cm) compared to inhibition of puberty alone +0.31 SDS (+1.92 cm), P=...

hrp0089p1-p018 | Adrenals and HPA Axis P1 | ESPE2018

Young Lean Women with Evidence of Both Premature Adrenarche and Pubarche Display a Metabolic, Hormonal and Psychologic Profile that is Similar to that of their Peers with Polycystic Ovary Syndrome

Livadas Sarantis , Bothou Christina , Kanaka-Gantenbein Christina , Chiotis Dimitrios , Angelopoulos Nicholas , Macut Djuro , Chrousos George P

Context: The early activation of adrenal zona reticularis, denoted by increased circulating levels of adrenal androgens before the age of eight years in girls is called premature adrenarche (PA), while the concomitant appearance of pubic hair is termed premature pubarche (PP). Girls with PA-PP display an unfavorable metabolic, hormonal and psychologic profile, compared to their normal peers and are also at an increased risk of developing polycystic ovary syndrome (PCO...

hrp0089p1-p187 | Growth &amp; Syndromes P1 | ESPE2018

A Novel Deadly Variant in the TP53 Gene Causing Li-Fraumeni Syndrome. The Importance of Clinical Awareness and the Contribution of Molecular Diagnosis in Active Prevention Within Families with Multiple Tumor Incidents at a Young Age

Bothou Christina , Spyridis Georgios P , Papantonatos Dionysios A , Stratakis Constantine A , Papadimitriou Dimitrios T

Background: Li-Fraumeni Syndrome (LFS) is an autosomal dominant hereditary cancer syndrome associated with germline pathogenic variants in in the TP53 gene and high risk of a broad range of early-onset malignancies. The 70-77% of LFS associated tumors are: breast cancer, soft-tissue sarcoma, brain tumor, osteosarcoma and adrenocortical carcinoma. However, ovarian, pancreatic and gastrointestinal track tumors are also LFS-related. The patients with LFS are at risk for a second ...

hrp0089p2-p290 | Multisystem Endocrine Disorders P2 | ESPE2018

Successful Treatment of Severe Atopic Dermatitis with Calcitriol and Paricalcitol in an 8-Year Old Girl

Bothou Christina , Alexopoulos Alexis , Dermitzaki Eleni , Kleanthous Kleanthis , Papadimitriou Anastasios , Mastorakos George , Papadimitriou Dimitrios T

Atopic dermatitis (AD) is a chronic inflammatory disease affecting children and adolescence. The traditional therapeutic options for AD, including emollients topically and immune modulatory agents systemically focusing on reducing skin inflammation and restoring the function of the epidermal barrier, are proven ineffective in many cases. Several studies have linked vitamin D supplementation with either a decreased risk to develop AD or a clinical improvement of the symptoms of...

hrp0089p1-p201 | Pituitary, Neuroendocrinology and Puberty P1 | ESPE2018

Anastrozole is Safe as Monotherapy in Early Maturing Girls with Compromised Growth, Further Improving Gain in Predicted Adult Height by the Initial Combination Therapy of an LHRH Analogue and an Aromatase Inhibitor: Results from the ‘Gail’ Study ISRCTN11469487

Dermitzaki Eleni , Kleanthous Kleanthis , Papagianni Maria , Attilakos Achilleas , Mastorakos George , Papadimitriou Anastasios , Papadimitriou Dimitrios T

Background: Third generation aromatase inhibitors (AI) have never been used as monotherapy, except for Mc Cune-Albright syndrome and autonomous ovarian cysts, to increase predicted adult height (PAH) in girls, mainly due to the theoretical concern of hyperandrogenism. Our previously published GAIL study [J Endocrinol Invest. 2016 Apr;39(4):439–46] has shown that the combination of anastrozole to an LHRH analogue for 24 months is safe and effective in ameliorating PAH in g...